Thirty Madison Real Customer Outcomes: An Independent Women's Health Review

What Thirty Madison Actually Is (And Is Not)

Thirty Madison is a holding company for a set of condition-specific telehealth brands, each built around one diagnosis category. It is not a general women's health platform, and it does not offer hormone therapy, fertility care, or menopause-specific services as of this writing. The brands under its portfolio include Keeps (hair loss), Cove (migraine), Evens (acid reflux and GI), Picnic (allergies), Facet (dermatology), and Brightside (mental health, now operating independently).

The business model is direct-to-consumer: you complete a symptom questionnaire online, a licensed clinician reviews it, and a prescription or OTC treatment plan ships to your door. Pricing is subscription-based, which can feel convenient but also creates a structure where the financial incentive is continuation of therapy rather than reassessment.

Why This Matters for Women Specifically

Women are not a secondary audience for most of these conditions. Migraine affects women at roughly three times the rate it affects men, with hormonal fluctuation across the menstrual cycle and perimenopause acting as a major trigger. Female pattern hair loss (androgenetic alopecia) affects an estimated 40-50% of women by age 50, yet the most prominent hair loss telehealth brands were built around male-pattern baldness first. Allergic rhinitis affects women and men at similar rates but symptom severity shifts across the menstrual cycle and pregnancy. A fair review of Thirty Madison requires asking whether the clinical framing and drug selection actually serve female patients well, not just whether the drugs work in general populations.

What the Portfolio Does Not Cover

Thirty Madison does not currently offer services for PCOS, endometriosis, perimenopause, menopause, thyroid disease, postpartum care, or GLP-1-based weight management. Women seeking help with those conditions will need a different platform. This is worth stating plainly before you spend time filling out intake forms.

Keeps: Hair Loss Treatment for Women

Keeps built its brand around men losing hair in their 20s and 30s. The clinical backbone was minoxidil topical solution and oral finasteride, both FDA-approved for androgenetic alopecia in men. The brand has since expanded to include women's hair loss offerings, but the expansion came second, and the clinical materials still reflect that.

What Keeps Prescribes for Women

For women, Keeps offers 2% or 5% topical minoxidil, which is FDA-approved for female pattern hair loss. The 5% foam formulation was studied in women and showed a statistically significant increase in non-vellus hair count at 48 weeks versus placebo in a randomized controlled trial. Oral minoxidil at low doses (0.625 mg to 2.5 mg daily) is increasingly used off-label for women and appears effective in several retrospective case series, though head-to-head RCT data in women remains limited.

Finasteride is where the women's story gets complicated. Keeps prescribes oral finasteride for men at 1 mg daily. Finasteride works by inhibiting 5-alpha reductase, lowering dihydrotestosterone (DHT). In post-menopausal women with androgenetic alopecia, some clinicians prescribe it off-label at doses between 1 mg and 5 mg, and a small number of trials suggest modest benefit. A 2023 systematic review in JAAD found low-quality evidence supporting finasteride 1-5 mg for female pattern hair loss, with most trials having fewer than 100 participants. The evidence gap here is real and Keeps should be more transparent about it.

Pregnancy and Lactation: Finasteride Is Category X

This is not a nuance. Finasteride is FDA Pregnancy Category X. Even topical exposure to crushed finasteride tablets can cause feminization of male fetuses. The FDA prescribing information states that finasteride is contraindicated in women who are or may potentially be pregnant. Thirty Madison's Keeps platform does ask about pregnancy status during intake. Women of reproductive age who are prescribed finasteride through any telehealth platform must use reliable contraception, and this requirement must be documented, not just checked off in a digital form.

Minoxidil in lactation: oral minoxidil is excreted in breast milk. The drug label advises against use in nursing women. Topical minoxidil at 2% has low systemic absorption, but data in breastfeeding women is sparse and caution is warranted.

Life Stage Considerations for Hair Loss

• Reproductive years: Hormonal hair shedding post-partum (telogen effluvium) is not androgenetic alopecia and does not respond to minoxidil the same way. An async telehealth intake may not distinguish these correctly. ACOG notes that postpartum hair loss typically self-resolves by 12 months.
• Perimenopause and menopause: This is when female pattern hair loss most commonly accelerates. Estrogen withdrawal changes the androgen-to-estrogen ratio at the follicle. Women in this stage may benefit most from minoxidil, and some data supports combining it with anti-androgens (spironolactone, not offered by Keeps) for better outcomes.
• PCOS: Androgen excess in PCOS drives hair thinning at the crown and temples. Keeps does not screen for PCOS, and treating hair loss without addressing the underlying hormonal driver is partial care at best.

Cove: Migraine Treatment for Women

Cove is the most clinically relevant Thirty Madison brand for women, and it is also the one where the sex-specific data is richest.

The Hormonal Migraine Problem

Approximately 70% of women with migraine report a relationship between their attacks and their menstrual cycle, with attacks clustering in the perimenstrual window when estradiol drops. Perimenopausal women often experience a worsening of migraine frequency as estrogen becomes more erratic. This is not a minor footnote. It is the dominant clinical story of migraine in women, and any migraine telehealth service should address it.

Cove prescribes a range of acute and preventive medications: triptans (sumatriptan, rizatriptan), gepants (ubrogepant, rimegepant), and preventives including topiramate, propranolol, amitriptyline, and the CGRP monoclonal antibodies (erenumab, fremanezumab via specialty pharmacy).

Sex-Specific Pharmacology at Cove

Triptans: Women metabolize some triptans differently than men. A pharmacokinetic analysis found that women show approximately 30-40% higher plasma concentrations of sumatriptan after subcutaneous injection compared to men, partly explained by lower body weight and volume of distribution differences. This is rarely discussed in direct-to-consumer migraine content, but it matters for dosing and for understanding why some women experience more side effects at standard doses.

CGRP levels fluctuate across the menstrual cycle, and the CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) studied in women show strong efficacy: in the ARISE trial, erenumab 70 mg reduced monthly migraine days by 2.9 days versus 1.8 days for placebo. Women made up roughly 85% of that trial population, which is unusually representative.

Pregnancy, Lactation, and Contraception: Topiramate Is a Teratogen

Topiramate (a common preventive at Cove) is FDA Pregnancy Category D. Topiramate is associated with an increased risk of oral clefts in infants exposed in utero, and the FDA issued a specific Safety Communication on this risk. Women of reproductive age prescribed topiramate require effective contraception. Topiramate also reduces the efficacy of combined hormonal contraceptives at doses above 200 mg/day, though the doses used for migraine prevention (25-100 mg/day) have a smaller interaction, it is not zero.

Triptans in pregnancy: The American Headache Society summarized evidence suggesting sumatriptan does not appear to increase major birth defect risk based on registry data, but the evidence base is limited and most neurologists recommend avoiding triptans in the first trimester if possible.

CGRP monoclonal antibodies: No adequate human pregnancy data exists. ACOG guidance recommends discontinuing CGRP-targeted therapies at least five half-lives before a planned conception. Cove should be counseling women on this at intake and at every renewal for women of reproductive age. Whether it does consistently through async messaging is unclear.

Perimenopausal and Postmenopausal Migraine

The Menopause Society notes that estrogen fluctuations during perimenopause often worsen migraine frequency before improvement occurs after menopause. For some women, low-dose transdermal estradiol used as a patch during the perimenstrual or perimenopausal window can reduce attack frequency. Cove does not prescribe hormone therapy, so women at this life stage may need to coordinate care between Cove and a separate menopause prescriber, which creates fragmentation.

Evens: GI and Acid Reflux

Evens targets GERD and acid reflux with PPI therapy (omeprazole, pantoprazole) and H2 blockers (famotidine). This is a condition that affects women differently than men in several ways that an async telehealth platform may not capture well.

Women with GERD are more likely to present with atypical symptoms (chronic cough, throat clearing, regurgitation) rather than classic heartburn, which can lead to underdiagnosis or misattribution of symptoms. Pregnancy dramatically increases reflux risk due to progesterone-mediated relaxation of the lower esophageal sphincter. PPIs are generally considered safe in pregnancy, though the FDA notes that data is limited and the lowest effective dose for the shortest duration is preferred.

Evens is arguably the simplest of the Thirty Madison brands from a clinical complexity standpoint. The drugs are widely studied, generic, and inexpensive. The main value proposition is convenience rather than clinical differentiation.

Bone Health and Long-Term PPI Use in Women

This matters especially for perimenopausal and postmenopausal women. Long-term PPI use (more than one year) is associated with a modestly increased risk of hip fracture, with one meta-analysis reporting an odds ratio of approximately 1.26 in postmenopausal women. A subscription-based model that auto-renews PPI prescriptions without scheduled reassessment could quietly contribute to unnecessary long-term use in a population already at elevated fracture risk.

Picnic: Allergy Treatment

Picnic offers antihistamine and nasal corticosteroid therapy for allergic rhinitis. The clinical picture for women is more hormonally textured than most allergy content acknowledges.

Estrogen receptors are present on mast cells, and estrogen can potentiate histamine release, which may explain why allergy symptoms often worsen premenstrually and during pregnancy. Pregnancy rhinitis (non-allergic) is frequently confused with allergic rhinitis, and the treatment approach differs. Picnic's async intake is unlikely to reliably distinguish the two.

For pregnancy: intranasal budesonide is considered compatible with pregnancy and is the preferred intranasal corticosteroid per ACOG guidance on rhinitis management in pregnancy. Oral antihistamines: loratadine and cetirizine are considered low-risk in pregnancy. First-generation antihistamines (diphenhydramine) are generally avoided in the third trimester due to neonatal sedation risk.

Who Thirty Madison Is Right For (and Who It Is Not)

This framework is designed to help women decide whether any Thirty Madison brand fits their current life stage and clinical situation.

Likely a reasonable fit:

• A post-menopausal woman with stable female pattern hair loss who wants minoxidil without an in-person dermatology appointment
• A woman in her 30s or 40s with well-characterized episodic migraine (no aura, no cardiovascular risk factors) who wants triptan access and has seen a clinician previously
• Any woman who needs convenient refills for a previously diagnosed condition and understands the platform is not a substitute for comprehensive care

Likely not an adequate fit:

• A woman of reproductive age prescribed finasteride or topiramate who does not have a clear contraception plan documented with the prescriber
• A perimenopausal woman whose migraine frequency is worsening and who needs hormonal evaluation alongside acute treatment
• A woman with PCOS-related hair loss or hormonal acne who needs anti-androgen therapy or a metabolic workup
• A pregnant or breastfeeding woman who has not discussed drug safety with a clinician experienced in obstetric pharmacology
• Anyone with a new, undiagnosed symptom pattern who needs a differential diagnosis, not a condition-specific intake form

Is Thirty Madison Legit? An Honest Assessment

The clinicians are licensed. The drugs are real and FDA-approved. The prices are generally lower than seeing a specialist out-of-pocket for straightforward cases. That much is legitimate.

What does not hold up as well: the patient outcomes data. A 2021 review of direct-to-consumer telehealth platforms published in JAMA found that most D2C platforms do not publish peer-reviewed outcomes data from their own patient cohorts, and Thirty Madison is not an exception. When Thirty Madison references "clinical outcomes" in marketing, those references point to evidence for the drug, not evidence that their particular platform achieves those outcomes at population scale in their specific patient mix. That distinction is meaningful and understated in their consumer-facing content.

A separate 2022 cross-sectional study in JAMA Internal Medicine found that D2C telehealth platforms for hair loss, migraine, and ED frequently prescribed medications without adequately assessing contraindications. The study did not name Thirty Madison specifically, but it describes the category risk that applies to async-first platforms generally. Women with hormonal contraindications or pregnancy considerations are the most exposed to these category risks.

Thirty Madison vs. Alternatives for Women

| Condition | Thirty Madison Brand | Alternative with Stronger Women's Focus | |---|---|---| | Hair loss | Keeps | Hims & Hers (Her platform), dermatology via Teladoc | | Migraine | Cove | Alto Pharmacy, Nurx (also prescribes hormonal migraine management) | | GI/reflux | Evens | Primary care via telehealth (Teladoc, MDLive) | | Allergy | Picnic | Primary care or allergist via telehealth | | Menopause/hormones | Not offered | Midi Health, Alloy, Gennev | | PCOS | Not offered | WomanRx, Nourish, Allara |

For women whose primary needs fall in the menopause, perimenopause, PCOS, fertility, or postpartum space, Thirty Madison is the wrong platform. A telehealth company that explicitly centers women's hormonal physiology at every life stage will serve those needs better.

Pregnancy, Lactation, and Contraception Summary (All Brands)

This section consolidates the pregnancy and lactation safety information for all drugs commonly prescribed across the Thirty Madison portfolio.

| Drug | Pregnancy Category | Lactation | Contraception Requirement | |---|---|---|---| | Finasteride (Keeps) | Category X. Contraindicated. | Contraindicated | Yes. Required for all women of reproductive age | | Oral minoxidil (Keeps) | Limited data; avoid | Excreted in breast milk; avoid | Discuss with prescriber | | Topical minoxidil 2% (Keeps) | Low systemic absorption; limited data | Low data; caution advised | No formal requirement; discuss | | Topiramate (Cove) | Category D. Oral cleft risk | Excreted in milk; monitor infant | Yes. Also reduces hormonal contraceptive efficacy at high doses | | Sumatriptan (Cove) | No clear major risk per registry data; avoid 1st trimester if possible | Low transfer; generally compatible | No formal requirement | | CGRP mAbs (Cove) | No adequate human data; discontinue pre-conception | Unknown; avoid | Discontinue 5 half-lives before conception | | Omeprazole/PPIs (Evens) | Generally considered low risk; use lowest dose | Compatible at low doses | No formal requirement | | Intranasal budesonide (Picnic) | Preferred INS in pregnancy | Compatible | No formal requirement | | Loratadine/cetirizine (Picnic) | Low risk | Compatible | No formal requirement |

ACOG's general guidance on medication use in pregnancy and the LactMed database maintained by the NIH are the most reliable up-to-date references for drug-specific breastfeeding safety.

How Much Does Thirty Madison Cost?

Pricing is brand-specific and changes with subscription tier.

• Keeps: Minoxidil topical starts around $10/month for 2% solution. Finasteride (for men) runs approximately $20-$25/month. Women's hair plans with consultation included start around $30-$40/month.
• Cove: Acute migraine treatment (generic triptan) starts around $10-$30/month depending on formulation. Preventive plans with CGRP monoclonal antibodies can run significantly higher, often $600-$700+/month before insurance. Cove does work with insurance for some medications.
• Evens: Generic omeprazole plans start around $20-$30/month including the consultation fee.
• Picnic: Allergy plans run approximately $30-$45/month for a personalized antihistamine or nasal steroid regimen.

None of these costs include lab work, which is sometimes needed for safe prescribing (e.g., a thyroid panel before attributing hair loss to androgenetic alopecia, or a lipid panel before starting a triptan in a woman with cardiovascular risk factors). That diagnostic gap is a real limitation of the async model, and you should budget for it.